Cargando…

Diagnostic and prognostic performance of CSF α‐synuclein in prion disease in the context of rapidly progressive dementia

INTRODUCTION: Surrogate cerebrospinal fluid (CSF) biomarkers of neurodegeneration still have a central role in the first‐line screening of patients with suspected Creutzfeldt‐Jakob disease (CJD). Recently, CSF α‐synuclein, a marker of synaptic damage, showed a close to optimal performance in disting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastrangelo, Andrea, Baiardi, Simone, Zenesini, Corrado, Poleggi, Anna, Mammana, Angela, Polischi, Barbara, Ladogana, Anna, Capellari, Sabina, Parchi, Piero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cerebrospinal Fluid Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240124/ https://www.ncbi.nlm.nih.gov/pubmed/34222611 http://dx.doi.org/10.1002/dad2.12214

Ejemplares similares

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
por: Skillbäck, Tobias, et al.
Publicado: (2021)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
por: DeMarco, Mari L., et al.
Publicado: (2020)

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease‐Opportunities for Therapy
por: Carare, Roxana O., et al.
Publicado: (2020)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys
por: Boehnke, Susan E., et al.
Publicado: (2020)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Deciphering the factors that influence participation in studies requiring serial lumbar punctures
por: Day, Gregory S., et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Association of cognitive impairment severity with potentially avoidable readmissions: A retrospective cohort study of 8897 older patients
por: Mitsutake, Seigo, et al.
Publicado: (2021)

Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study
por: Clark, Alexandra L., et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta status
por: Morar, Ulyana, et al.
Publicado: (2022)

Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991)

Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
por: Bentivenga, Giuseppe Mario, et al.
Publicado: (2023)

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia
por: Abu-Rumeileh, Samir, et al.
Publicado: (2019)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

The Use of Real-Time Quaking-Induced Conversion for the Diagnosis of Human Prion Diseases
por: Poleggi, Anna, et al.
Publicado: (2022)

The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias
por: Abu-Rumeileh, Samir, et al.
Publicado: (2018)

Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes
por: Quadalti, Corinne, et al.
Publicado: (2021)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume
por: Sapkota, Shraddha, et al.
Publicado: (2022)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings
por: Baiardi, Simone, et al.
Publicado: (2015)

Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study
por: Vacchiano, Veria, et al.
Publicado: (2021)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vosh87tq246bh52dvbnr5g1iqc